Serological under expression of microRNA-21, microRNA-34a and microRNA-126 in colorectal cancer

AUTOR(ES)

Almeida, Ana Luiza Normanha Ribeiro de, Bernardes, Mário Vinícius Angelete Alvarez, Feitosa, Marley Ribeiro, Peria, Fernanda Maris, Tirapelli, Daniela Pretti da Cunha, Rocha, José Joaquim Ribeiro da, Feres, Omar

FONTE

Acta Cir. Bras.

DATA DE PUBLICAÇÃO

2016

RESUMO

PURPOSE: This paper describes the ability of miRNA value predict oncological outcomes in CRC patients and correlates to clinical and pathologic variables. METHODS: We prospectively analyzed the serological expression of microRNA-21, microRNA-34a, and microRNA-126 in 37 stage II - IV CRC patients and correlate to seven fit counterparts. Serological microRNAs were extracted using the miRNeasy Mini Kit(r) (Qiagen, Hilden, Germany). Quantification of microRNAs was performed using TaqMan Master Mix(r) reagent (Applied Biosystems, USA). RESULTS: We obtained serological underexpression microRNA-21, microRNA-34a, and microRNA-126 in CRC group. However, miRNAs serological values do not impact prognosis. Furthermore, miRNAs was not influenced by CEA values, TNM staging, and histological subtype. CONCLUSION: Despite lower expression of miR-21, miR-34a and miR-126 in the CRC group, no association with poor prognosis was found.

Documentos Relacionados

• Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease
• MicroRNA Expression Signature and the Role of MicroRNA-21 in the Early Phase of Acute Myocardial Infarction*
• MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer
• MicroRNA-451a, microRNA-34a-5p, and microRNA-221-3p as predictors of response to antidepressant treatment
• Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors